Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

Vaccine

Volumn 25, Issue 50, 2007, Pages 8480-8485

  Belsher, Jon L ^a   Gay, Peter ^a   Brinton, Margo ^b   DellaValla, Joseph ^c   Ridenour, Robert ^a   Lanciotti, Robert ^d   Perelygin, Andrey ^b   Zaki, Sherif ^d   Paddock, Christopher ^d   Querec, Troy ^e   Zhu, Tuofu ^f   Pulendran, Bali ^e   Eidex, Rachel B ^d   Hayes, Edward ^d  

^a Mayo Clinic   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Portage Health System   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Yellow fever; Yellow fever vaccination; Yellow fever vaccine associated viscerotropic disease

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HYDROCORTISONE; IMMUNOGLOBULIN; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; ENTEROPATHY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEREDITY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOST SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MORTALITY; MULTIPLE ORGAN FAILURE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOGENICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VISCEROTROPHIC DISEASE; VISCEROTROPIC DISEASE; VITAL SIGN; YELLOW FEVER;

ADULT; FATAL OUTCOME; FEMALE; HUMANS; MULTIPLE ORGAN FAILURE; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 36249021519     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.061     Document Type: Article

References (23)

1. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18 5 (2005) 387-394
2. Monath T.P. Yellow fever vaccine. 4th ed. (2004), Philadelphia, Saunders
3. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 4 4 (2005) 553-574
4. Martin M., Tsai T., Cropp B., Chang G., Holmes D., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 9276 (2001) 98-104
5. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23 25 (2005) 3256-3263
6. Barwick R. History of thymoma and yellow fever vaccination. Lancet 364 9438 (2004) 936
7. Vasconcelos P., Luna E., Galler R., Silva L., Coimbra T., Barros V., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 9276 (2001) 91-97
8. Doblas A., Domingo C., Bae H., Bohórquez C., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36 2 (2006) 156-158
9. Gerasimon G., and Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 98 6 (2005) 653-656
10. Perelygin A.A., Scherbik S.V., Zhulin I.B., Stockman B.M., Li Y., and Brinton M.A. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 99 14 (2002) 9322-9327
11. Bonnevie-Nielsen V., Heron I., Monath T.P., and Calisher C.H. Lymphocytic 2′,5′-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 2 3 (1995) 302-306
12. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.F., Frank W.A., et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203 1 (2006) 35-40
13. Yakub I., Lillibridge K.M., Moran A., Gonzalez O.Y., Belmont J., Gibbs R.A., et al. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 192 10 (2005) 1741-1748
14. Guarner J., Bartlett J., Reagan S., Fischer M., Finn S., O'Briain D., et al. Immunohistochemical evidence of Clostridium sp, Staphylococcus aureus, and group A Streptococcus in severe soft tissue infections related to injection drug use. Hum Pathol 37 11 (2006) 1482-1488
15. Pal S., and Schnapp L.M. HIV-infected lymphocytes regulate fibronectin synthesis by TGF beta 1 secretion. J Immunol 172 5 (2004) 3189-3195
16. Liu H., Hwangbo Y., Holte S., Lee J., Wang C., Kaupp N., et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 190 6 (2004) 1055-1058
17. Liu H., Carrington M., Wang C., Holte S., Lee J., Greene B., et al. Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. J Infect Dis 193 5 (2006) 698-702
18. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169 3 (1994) 512-518
19. Bonnevie-Nielsen V., Field L.L., Lu S., Zheng D., Li M., Martensen P.M., et al. Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 76 4 (2005) 623-633
20. Torshin I.Y. Three-dimensional models of human 2′-5′ oligoadenylate synthetases: a new computational method for reconstructing an enzyme assembly. Med Sci Monit 11 7 (2005) BR235-BR247
21. Hamano E., Hijikata M., Itoyama S., Tran Q., Nguyen C.P., Hoang T.L., et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun 329 4 (2005) 1234-1239
22. Paddock C.D., Nicholson W.L., Bhatnagar J., Goldsmith C.S., Greer P.W., Hayes E.B., et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis 42 11 (2006) 1527-1535
23. Jones E.M., and Wilson D.C. Clinical features of yellow fever cases at Vom Christian Hospital during the 1969 epidemic on the Jos Plateau, Nigeria. Bull World Health Organ 46 5 (1972) 653-657